
European practitioners will gain new methods for treatment after the June meeting of the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) where the panel recommended several novel drug candidates and new indications for existing drugs.
Celgene's gene therapy Abecma (idecabtagene vicleucel) was for example nominated for conditional marketing authorization as a fourth-line therapy for bone marrow cancer. CHMP also had a positive view of Biomarin's Voxzogo (vosoritid) for the day-to-day treatment of children with achondroplasia. This drug might eventually challenge Transcon CNP, which is produced by Danish biotech firm Ascendis, if the latter reaches the market.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app